Parabilis Medicines

We’re thrilled to celebrate the well-earned promotions of #TeamParabilis. Every day, our team brings curiosity, creativity, and commitment to the work of unlocking new therapeutic potential for patients with devastating diseases. Congratulations to Nathan Chui, Mallika Iyengar, George Sabin, Archana Iyer, Tara Travaline, Colby Fees, PhD, Lifeng Yuan, Su Yan, Tomer Faraggi, Anthony Quartararo, Lindsay J. Moore, Heather Shannon Grant, Saad Tauhid, and John Cassidy on your new roles!  We’re excited to continue #CreatingExtraordinaryMedicines together. #TeamPromotions #ParabilisMedicines 

Parabilis EVP of Discovery Science, Markus Haeberlein, is taking the stage at the Hanson Wade 2nd Peptide-Based Therapeutics Summit.    Markus will present on our ongoing work using Helicons as protein degraders, expanding #TPD to historically “undruggable” targets such as β-catenin, ERG, and a novel approach to AR. Learn more about our pipeline of first-in-class Helicon degraders: https://lnkd.in/emMcHrRF     #PeptideSummit #Peptides #Helicons 

As we close out Colorectal Cancer Awareness Month, we’re grateful to the many nonprofit and advocacy groups who continue to raise awareness of #CRC – educating on the importance of screening, biomarkers, and clinical trials. Check out our #CRCAwarenessMonth posts on each of these topics to learn more.    We know better treatment options for CRC are urgently needed, and we are actively advancing clinical trials of FOG-001 to explore its potential as a meaningful therapy for patients facing this disease.                      Together, we can help bend the curve to make #ColorectalCancer more detectable, more treatable, and more curable.    #ParabilisMedicines #CreatingExtraordinaryMedicines 

Clinical trials are essential in bringing new treatment options to patients with #ColorectalCancer. But it’s not always obvious how to access clinical trials or how to decide which trial to participate in.     Understanding the clinical trials system is key to making informed decisions. For those looking to learn more about clinical trials for patients with colorectal cancer, the experts at PALTOWN Development Foundation provide valuable insights in their recent webinar, “Clinical Trials Demystified." Watch the full recording here: https://lnkd.in/e2vqy3Y2    There are several clinical trials for colorectal cancer currently available at www.clinicaltrials.gov. Talk to your healthcare provider about whether a clinical trial may be right for you.     #CRCAwarenessMonth #ClinicalTrials #CRCSM 

Biomarkers are a valuable source of information for physicians treating patients with #ColorectalCancer. Biomarkers can help guide treatment decisions, determine prognosis, and monitor disease progression. They also play a key role in researchers’ development of targeted therapies designed to address the unique biology of each patient’s cancer.      For #CRCAwarenessMonth, take a moment to learn about biomarkers related to CRC: https://lnkd.in/e2hiQarF     The Global Colon Cancer Association has put together a wealth of resources to empower patients and caregivers to understand colorectal cancer biomarkers and biomarker testing, available at  www.knowyourbiomarker.org 

We were honored to recently host a #TeamParabilis discussion with two experienced physicians who are participating in our ongoing clinical trial of FOG-001. They shared about patients’ experiences of clinical trial participation, how clinical trials are enrolled, and their experiences treating patients with late-stage colorectal cancer and desmoid tumors.    Their perspectives inspired and reminded us of the importance of our work to fundamentally change treatment possibilities for #cancer.     #ParabilisMedicines #Biotech #ClinicalTrials #Oncology 

On Saturday, March 22, we’re heading to Wachusett Mountain Ski Area to ski for a cause. #TeamParabilis is organizing the Ski to Cure Cancer event benefiting the Joe Andruzzi Foundation, which helps New England cancer patients and their families with household expenses, food, and transportation while they are in treatment.    Full details of the event are at https://lnkd.in/et628tNM, and you can support our team by donating at:  https://lnkd.in/e5Tt3Jm8     #ParabilisMedicines #CRCAwarenessMonth #Cancer 

Rates of #colorectalcancer among young people are rising. Approximately 10% of all new diagnoses of colorectal cancer are occurring in people younger than 50.  If you're 45 or older, it's time to talk to your doctor about colorectal cancer screening.  Visit quiz.getscreened.org to take a quiz from the Colorectal Cancer Alliance to learn about your screening options.  #CRCAwarenessMonth #Oncology #CancerScreening 

What are you curious about? What does success mean to you? How do you celebrate professional wins? Parabilis CEO Mathai Mammen, M.D., Ph.D. answered these questions on NYSE's “The Cure(ious),” a round robin of leaders in life sciences who shared their insights, knowledge and personal perspectives that left us inspired about the future of health and wellness.    Mathai shared his perspective on the power of human connection, the importance of celebrating progress in #drugdiscovery and development, and how personal and professional success are intertwined — all of which are elements of the vibrant and passionate culture we’ve built. At Parabilis, we are making transformational medicines, leveraging our powerful Helicon peptide platform to target disease-causing proteins that have been undruggable to date. Watch the collection of videos here: https://lnkd.in/gT_VYeXN #ParabilisMedicines #Biotech #DrugDevelopment #Leadership 

In honor of #InternationalWomensDay, we took a moment to recognize and appreciate the incredible women on our team – and the women who have shaped our lives.       Over lunch catered by La Qchara, a local woman-owned business, #TeamParabilis wrote thank you notes to women who have been models and mentors in their lives.       A heartfelt thank you to everyone who participated and to the women of Parabilis who drive forward our mission of #CreatingExtraordinaryMedicines every day.